Anticancer Drug Therapy in the Older Cancer Patient: Pharmacology and Polypharmacy

[1]  H. Cohen,et al.  Senior adult oncology clinical practice guidelines in oncology. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  Lyndsay Harris,et al.  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  E. Winer,et al.  Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Richards,et al.  Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.

[5]  S. Oudard,et al.  Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management , 2007, Cancer.

[6]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[7]  H. Wildiers,et al.  Renal insufficiency in elderly cancer patients: International Society of Geriatric Oncology clinical practice recommendations. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  M. Meyerson,et al.  Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Barry,et al.  Inappropriate prescribing in the elderly: a comparison of the Beers criteria and the improved prescribing in the elderly tool (IPET) in acutely ill elderly hospitalized patients , 2006, Journal of clinical pharmacy and therapeutics.

[10]  M. Kris,et al.  Pharmacokinetics and Toxicity of Weekly Docetaxel in Older Patients , 2006, Clinical Cancer Research.

[11]  N. Hanna,et al.  Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  C. Tournigand,et al.  Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Hanlon,et al.  Assessing Potentially Inappropriate Prescribing in the Elderly Veterans Affairs Population Using the HEDIS 2006 Quality Measure , 2006, Journal of managed care pharmacy : JMCP.

[14]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Tsang,et al.  Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  K. Cannon,et al.  Potentially inappropriate medication use in elderly patients receiving home health care: a retrospective data analysis. , 2006, The American journal of geriatric pharmacotherapy.

[17]  G. Mann,et al.  Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  B. Bergman-Evans.  AIDES to improving medication adherence in older adults. , 2006, Geriatric nursing.

[19]  E. Jantunen,et al.  High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol , 2006, Bone Marrow Transplantation.

[20]  G. Rosner,et al.  Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Feliu,et al.  XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer , 2006, British Journal of Cancer.

[22]  A. Tolcher,et al.  Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  P. Catalano,et al.  Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Greg Yothers,et al.  Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  L. Osterberg,et al.  Adherence to medication. , 2005, The New England journal of medicine.

[26]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[27]  J. Feliu,et al.  Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Maryann M Fulton,et al.  Polypharmacy in the elderly: A literature review , 2005, Journal of the American Academy of Nurse Practitioners.

[29]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[30]  W. Scheithauer,et al.  Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  C. Alliot,et al.  Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly , 2004, British Journal of Cancer.

[32]  S. Lichtman.  Chemotherapy in the elderly. , 2004, Seminars in oncology.

[33]  D. Armstrong.  Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity. , 2004, The oncologist.

[34]  M. Beers,et al.  Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. , 2003, Archives of internal medicine.

[35]  G. Rosner,et al.  A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  J. Doroshow,et al.  Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Swain,et al.  Congestive heart failure in patients treated with doxorubicin , 2003, Cancer.

[38]  C. Fuchs,et al.  Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Laville,et al.  Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure. , 2002, Journal of nephrology.

[40]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[41]  R. Larson,et al.  Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study , 2002, Cancer Chemotherapy and Pharmacology.

[42]  David Cella,et al.  Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. , 2002, Journal of the National Cancer Institute.

[43]  D. Budman,et al.  The Pharmacokinetics and Pharmacodynamics of Fludarabine Phosphate in Patients with Renal Impairment: A Prospective Dose Adjustment Study , 2002, Cancer investigation.

[44]  R. Labianca,et al.  A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. , 2001, The New England journal of medicine.

[45]  C. Begg,et al.  Age and adjuvant chemotherapy use after surgery for stage III colon cancer. , 2001, Journal of the National Cancer Institute.

[46]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  G. Rosner,et al.  Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Goodman,et al.  A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer , 2000, Cancer investigation.

[49]  M. Buyse,et al.  Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  L. Grochow,et al.  Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan. , 1997, Gynecologic oncology.

[51]  M. Beers,et al.  Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. , 1997, Archives of internal medicine.

[52]  G. Rosner,et al.  Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062). , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  H. Wildiers,et al.  International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency. , 2007, European journal of cancer.

[54]  C. Seynaeve,et al.  Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. , 2003, European journal of cancer.

[55]  P. Burkhart,et al.  Adherence to long-term therapies: evidence for action. , 2003, Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing.

[56]  A. Calvert,et al.  Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. , 2002, European journal of cancer.

[57]  B. Reigner,et al.  Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients , 1999, Cancer Chemotherapy and Pharmacology.

[58]  N. Petrelli,et al.  Age and sex are independent predictors of 5‐fluorouracil toxicity. Analysis of a large scale phase III trial , 1995, Cancer.